Impact of Hepatitis B Core Antibody (HBcAb) Seropositivity on the Outcome of High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Abstract

to 8% and did not differ across regimens in multivariate analysis. There were a significant interaction between regimens and disease (HL and NHL). For patients with NHL, there was no significant difference in outcomes with BEAM, CBV low , BuCy, and TBI. In contrast, NHL patients treated with CBV high had higher progression (HR 1.28 [1.08, 1.50], p¼0.003), and mortality (HR 1.27 [1.08, 1.49], p¼0.003). For patients with HL, BuCy and TBI were associated with higher progression at 3 years compared to BEAM (47%, 57% vs. 36%) and shorter overall survival (65%, 47% vs. 79%). Multivariable results for HL are demonstrated in the table. Conclusion: The impact of specific high-dose regimens with AutoHCT on overall outcomes appears to be different in patients with NHL and HL. Use of CBV high in patients with NHL and BuCy or TBI-containing regimens in HL were associated with worse outcomes compared to BEAM. Future investigation should be geared towards guiding the choice of regimen based on specific patient and disease characteristics.